Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 1.00 |
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177950 | 0.87 | ATR (0.77) | ATRBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL10230626 | 0.85 | ATR (0.75) | ATRATMGSK3BPRKDC | |
| SCHEMBL10228677 | 0.85 | ATR (0.74) | ATRATMGSK3BPRKDC | |
| SCHEMBL10228722 | 0.85 | ATR (0.74) | ATRATMGSK3BPRKDC | |
| SCHEMBL10231258 | 0.83 | ATR (0.73) | ATRATMGSK3BPRKDC | |
| SCHEMBL18771103 | 0.81 | ATR (0.68) | ATRATMGSK3BPRKDC | |
| SCHEMBL10231215 | 0.80 | ATR (0.67) | ATRATMGSK3BPRKDC | |
| SCHEMBL10231213 | 0.80 | ATR (0.75) | ATRATMGSK3BPRKDC | |
| SCHEMBL18771090 | 0.80 | ATR (0.67) | ATRATMGSK3BPRKDC | |
| SCHEMBL10231261 | 0.78 | ATR (0.63) | ATRATMGSK3BPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | ATR 1/4885ATM 32/4885GSK3B 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.